Sight Sciences, Inc. (SGHT)

Surgical & Medical Instruments & Apparatus · market cap $465M · as of 2026-07-10

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Sight Sciences (SGHT) is a ~$291M market cap medical device/biotech hybrid with a commercial-stage surgical business generating ~$77M in annual revenue and a pipeline asset, BS01, currently in Phase 2 development for Retinitis Pigmentosa (RP). The company carries $85M in cash with an estimated 36-month runway, providing a meaningful buffer before the key Phase 2 BS01 readout expected around end of 2026.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10
2026-12-30 (est.)Phase 2 · BS01imp 7/10

Pipeline

Asset	Phase	Indication
BS01	Phase 2	Retinitis Pigmentosa

Price & technical context

3-month

+58.2%

6-month

+146.3%

12-month

+158.8%

52-wk range

$3.20–$9.36

vs 50-day MA

+11.3%

vs 200-day MA

+47.0%

Realized vol

80.9%

Max drawdown

-69.9%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for SGHT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.